Markus Velten

Prof. Dr. Markus Velten

Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 153127 Bonn, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Radiology
Verified
Journal Article
Closed access
DKDmitrij Kravchenko
Dmitrij Kravchenko
AIAlexander Isaak
Alexander Isaak
SZSebastian Zimmer
Sebastian Zimmer
NMNarine Mesropyan
Narine Mesropyan
MRMatthäus Reinert
Matthäus Reinert
JLJulian A. Luetkens
Julian A. Luetkens
Previously healthy individuals with prolonged cardiorespiratory symptoms after SARS-CoV-2 infection who were not hospitalized at any disease stage had no signs of active cardiac inflammation at car... Background Myocardial injury and inflammation at cardiac MRI in patients with COVID-19 have been described in recent publications. Concurrently, a chronic COVID-19 syndrome (CCS) after SARS-CoV-2 i...

31 July 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
GMGhaith Mohsen
Ghaith Mohsen
ASAnnika Stroemer
Annika Stroemer
AMAndreas Mayr
Andreas Mayr
AKAndrea Kunsorg
Andrea Kunsorg
CSChristian Stoppe
Christian Stoppe
Markus VeltenMarkus Velten
Markus Velten
Initial evidence indicates that preoperatively initiated administration of omega-3 fatty acids (FAs) attenuates the postoperative inflammatory reaction. The effects of immunonutrition containing omega-3 FAs, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), on the inflammatory response to abdominal surgery continues to be unclear, although improved outcomes have been reported. Therefore, we determined the effectiveness of preoperatively initiated omega-3 FAs administration on postoperative inflammation defined as CRP (C-Reactive Protein), IL-6 (Interleukin 6), and WBC (White Blood Count) and potential effects on postoperative length of hospital stay (LOS) due to an improved inflammatory response. Methods: a literature search of Cochrane Library was conducted to identify all randomized controlled trials (RCTs) investigating the effects of preoperatively initiated omega-3 to standard care, placebo, or other immunonutrients excluding omega-3 FAs in patients undergoing abdominal surgery until the end of December 2022. Results: a total of 296 articles were found during the initial search. Thirteen RCTs involving 950 patients were identified that met the search criteria. These were successively analyzed and included in this meta-analysis. There was no significant difference between the groups with respect to inflammatory markers IL-6: −0.55 [−1.22; 0.12] p = 0.10, CRP: −0.14 [−0.67; 0.40] p = 0.55, WBC: −0.58 [−3.05; 1.89] p = 0.42, or hospital stay −0.5 [−1.43; 0.41] p = 0.2. Conclusion: although reduced inflammatory markers were observed, preoperative administration of omega-3 FAs immunonutrients had no significant effect on the postoperative inflammatory response in patients undergoing abdominal surgeries. Yet, results obtained from this study are inconclusive, likely attributed to the limited number of trials and patients included. Further studies are required to obtain a better educated verdict.

4 February 2019 in Trials
Verified
Journal Article
Open access
PDF file
LGLIBERAL Collaboration Group
LIBERAL Collaboration Group
PMPatrick Meybohm
Patrick Meybohm
SLSimone Lindau
Simone Lindau
STSascha Treskatsch
Sascha Treskatsch
RFRoland Francis
Roland Francis
KZKai Zacharowski
Kai Zacharowski
Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less compensatory mechanisms because of multiple co-morbidities and age-related decline of functional reserves. The purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC) transfusion strategy compared to a restrictive transfusion strategy. The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising 2470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will be randomised only if Haemoglobin (Hb) reaches ≤9 g/dl during surgery or within 3 days after surgery either to the LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb level of 9–10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target range for the post-transfusion Hb level of 7.5–9 g/dl). The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III), acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect. The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90 days after surgery. ClinicalTrials.gov (identifier: NCT03369210 ).

1 April 2021 in Radiology: Cardiothoracic Imaging
Verified
Journal Article
Closed access
JLJulian A. Luetkens
Julian A. Luetkens
AIAlexander Isaak
Alexander Isaak
CÖCan Öztürk
Can Öztürk
NMNarine Mesropyan
Narine Mesropyan
MMMalte Monin
Malte Monin
JNJacob Nattermann
Jacob Nattermann
Keywords: COVID-19; coronavirus; myocarditis; cardiac MRI; T1 mapping; T2 mapping

1 January 2021 in Redox Biology
Verified
Journal Article
Open access
MRMary E Robbins
Mary E Robbins
Hye-Youn ChoHye-Youn Cho
Hye-Youn Cho
JHJason M. Hansen
Jason M. Hansen
JLJoseph R. Luchsinger
Joseph R. Luchsinger
MLMorgan L. Locy
Morgan L. Locy
TTTrent E. Tipple
Trent E. Tipple
Cellular antioxidants protect against hyperoxic lung injury. The role of the glutathione (GSH) system in lung development and bronchopulmonary dysplasia (BPD) pathogenesis has not been systematically investigated. The current study utilized GSH reductase-deficient (Gsr-KO) neonatal mice to test the hypothesis that early disruption of the GSH system negatively impacts lung development and hyperoxic responses. Lungs from wild-type (Gsr-WT) and Gsr-KO mice were analyzed for histopathology, developmental markers, redox indices, and transcriptome profiling at different developmental stages following exposure to room air or hyperoxia (85% O2) for up to 14 d. Lungs from Gsr-KO mice exhibited alveolar epithelial dysplasia in the embryonic and neonatal periods with relatively normal lung architecture in adulthood. GSH and its oxidized form (GSSG) were 50-70% lower at E19-PND14 in Gsr-KO lungs than in age-matched Gsr-WT. Differential gene expression between Gsr-WT and Gsr-KO lungs was analyzed at discrete developmental stages. Gsr-KO lungs exhibited downregulated cell cycle and DNA damage checkpoint genes at E19, as well as lung lipid metabolism and surfactant genes at PND5. In addition to abnormal baseline lung morphometry, Gsr-KO mice displayed a blunted response to hyperoxia. Hyperoxia caused a more robust upregulation of the lung thioredoxin system in Gsr-KO compared to Gsr-WT. Gsr-dependent, hyperoxia-responsive genes were highly associated with abnormal cytoskeleton, skeletal-muscular function, and tissue morphology at PND5. Overall, our data in Gsr-KO mice implicate the GSH system as a key regulator of lung development, cellular differentiation, and hyperoxic responses in neonatal mice.

1 September 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TBTorsten Baehner
Torsten Baehner
PPPhilipp Christopher Prümm
Philipp Christopher Prümm
MVMathieu Vergnat
Mathieu Vergnat
BABoulos Asfour
Boulos Asfour
NSNadine Straßberger-Nerschbach
Nadine Straßberger-Nerschbach
Maria WittmannMaria Wittmann
Maria Wittmann
Background: Enhanced recovery after surgery (ERAS) protocols are utilizing a multidisciplinary approach, reassessing physiology to improve clinical outcomes, reducing length of hospital stay (LOS) stay, resulting in cost reduction. Since its introduction in colorectal surgery. the concept has been utilized in various fields and benefits have been recognized also in adult cardiac surgery. However, ERAS concepts in pediatric cardiac surgery are not yet widely established. Therefore, the aim of the present study was to assess the effects of on-table extubation (OTE) after pediatric cardiac surgery compared to the standard approach of delayed extubation (DET) during intensive care treatment. Study Design and Methods: We performed a retrospective analysis of all pediatric cardiac surgery cases performed in children below the age of two years using cardiopulmonary bypass at our institution in 2021. Exclusion criteria were emergency and off pump surgeries as well as children already ventilated preoperatively. Results: OTE children were older (267.3 days vs. 126.7 days, p < 0.001), had a higher body weight (7.0 ± 1.6 kg vs. 4.9 ± 1.9 kg, p < 0.001), showed significantly reduced duration of ICU treatment (75.9 ± 56.8 h vs. 217.2 ± 211.4 h, p < 0.001) and LOS (11.1 ± 10.2 days vs. 20.1 ± 23.4 days; p = 0.001) compared to DET group. Furthermore, OTE children had significantly fewer catecholamine dependencies at 12-, 24-, 48-, and 72-h post-surgery, while DET children showed a significantly increased intrafluid shift relative to body weight (109.1 ± 82.0 mL/kg body weight vs. 63.0 ± 63.0 mL/kg body weight, p < 0.001). After propensity score matching considering age, weight, bypass duration, Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery Mortality (STATS)-Score, and the outcome variables, including duration of ICU treatment, catecholamine dependencies, and hospital LOS, findings significantly favored the OTE group. Conclusion: Our results suggest that on-table extubation after pediatric cardiac surgery is feasible and in our cohort was associated with a favorable postoperative course.